The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 15, 2022

Filed:

Oct. 12, 2021
Applicant:

Inventisbio Co., Ltd., Shanghai, CN;

Inventor:

Yueheng Jiang, Shanghai, CN;

Assignee:

INVENTISBIO CO., LTD., Shanghai, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 403/04 (2006.01); A61P 35/02 (2006.01); A61P 35/04 (2006.01); A61K 31/506 (2006.01); C07D 471/04 (2006.01); C07D 401/04 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 401/14 (2006.01); C07D 413/04 (2006.01); C07D 417/04 (2006.01); A61K 31/437 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/437 (2013.01); A61K 31/506 (2013.01); A61P 35/02 (2018.01); A61P 35/04 (2018.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 413/04 (2013.01); C07D 417/04 (2013.01);
Abstract

The present invention disclosed a class of pyrimidine or pyridine compounds, pharmaceutically acceptable salts, stereoisomers, prodrugs and solvates thereof, preparation method therefor and pharmaceutical compositions and pharmaceutical uses thereof. See e.g., Formula I below. The compounds can inhibit the variants of EGFR (Epidermis Growth Factor Receptor) proteinases, and therefore can inhibit the growth of a variety of tumor cells effectively. The compounds can be used to prepare antitumor drugs, used for the treatment, combined therapy or prevention of various different cancers. The compounds can overcome the drug resistance induced by the existing first-generation EGFR inhibitors such as gefitinib, erlotinib and so on. Particularly, the compounds can be used to prepare drugs for treating or preventing diseases, disturbances, disorders or conditions mediated by epidermis growth factor receptor variants (such as L858R activated mutants, Exon19 deletion activated mutants and T790M resistant mutants).


Find Patent Forward Citations

Loading…